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Introduction 
Micro RNAs (miRNAs) are small (~22 nucleotide long) non-cod-
ing RNAs that regulate gene expression at the post-transcriptional 
level by degradation of  mRNAs or inhibition of  protein transla-
tion [1]. The first micro RNA, lin-4, was discovered in Caeno-
rhabditiselegans (C. elegans) by Rosalind C. Lee et al in 1993 [2]. 
Currently,over 1600 miRNA precursors are thought to be includ-
ed in the human genome, producing over 2,000 mature miRNAs 
[3]. Initially thought to have little significance it is now known that 
microRNAs play crucial roles in many biological processes such 
as cell growth, embryogenesis, apoptosis, and are also involved in 
numerous disease processes [4].
Peripheral arterial disease is caused by atherosclerosis leading to 
narrowing of  the blood flow to the lower limbs. This leads to two 
distinct clinical manifestations, symptoms of  discomfort and pain 
on walking known as intermittent claudication (IC) or pain at rest 
sometimes associated with gangrene or ulceration also known as 
critical limb ischemia (CLI). Risk factors for PAD include ciga-
rette smoking, diabetes mellitus (type 1 and 2), hypertension, hy-
percholesterolemia, hyperhomocysteinemia, elevated fibrinogen 
levels and elevated C-reactive protein level [6].  In individuals with 
PADand diabetes, the disease is more likely to develop below the 
knee (femoral-popliteal and tibial) while those without diabetes 
are more likely to develop proximal disease (aorto-ilio-femoral) 
[7]. Many individuals with diabetes suffer from peripheral neu-
ropathy, resulting in impaired sensory function.  As a result, the 
classic history of  claudication may be less common in these indi-
viduals [7].  Moreover, as much as 1/3 to 1/2 of  individuals with 
PAD remain without the 2 classic symptoms of  PAD. Approxi-
mately 8 millions Americans are affected with PAD, with Afri-
can Americans having higher rates [8].PAD affects up to 10% of  
people younger than 70 and 15-20% of  those older than 70 [9].
About 10% of  individuals with IC go on to develop CLI within 
5 years [10].Within the first year after presentation an estimated 
25% of  patients with CLI die, 35% remain alive with amputations, 
25% have resolution while 20% continue to be symptomatic [10]. 
The burden on the health system has been catastrophic, with an 
estimated 4 billion dollars spent on PAD related treatment in the 
year 2001 [11].
The diagnosis of  PAD begins with a thorough history and exami-
nation of  the patient. Several test are available to diagnose PAD, 
however themost common initial test used is the ankle-brachial 
index (ABI). The test involves measuring the blood pressure in 
the ankle compared to that in the arm to give an idea of  the cir-
culation of  blood. A normal ABI value ranges from 0.9-1.3, while 
values ≤ 0.9 are considered diagnostic and values greater than 1.4 
are abnormal, indicating non-compressible arteries. In patients 
with rigid arteries a toe brachial index (TBI) is usually indicated. 
Beyond  the ABI Further tests may be indicated to help localize 
the occlusion as well as determine disease severity, these include 
Doppler ultrasound, magnetic resonance angiogram and arterio-
gram [12].
 
To date, the general treatment of  PAD involves improving walk-
ing distance and reducing risk factors to decrease associatedmor-
bidity and mortality. Two important management strategies in-
volve smoking cessation and exercise [13]. Medications that have 
been used in the treatment of  PAD include cilostazol, statins, cal-
cium channel blockers and antithrombotic therapy [14-17] How-
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ever, these medications have not been very effective in treating 
the main defect in PAD i.e they are not very effective in improv-
ing perfusion. 
The adaptive process of  neovascularization following vascular oc-
clusion is an important mechanism involved in perfusion recov-
ery [18]. The area distal to the occlusion suffers from ischemia, 
which promotes proliferation of  preexisting collateral arteries and 
formation of  new capillaries [19]. An approach to the treatment 
of  CLI known as therapeutic angiogenesis has gained some at-
tention. The idea of  therapeutic angiogenesis involves promoting 
the growth of  new blood vessels or changes in existing vessels in 
order to improve blood flow.Although a number of  angiogenic 
factors have been successfully used for therapeutic angiogenesis 
in pre-clinical models (eg. VEGF, FGF, and HGF), these agents 
have had very limited success in human clinical studies [6,20,21].
Therefore, other approaches are being investigated to explore the 
possibility of  bringing the promise of  therapeutic angiogenesis to 
fruition. One approach includes the investigation of  miRNAs as 
a potential factor that could be manipulated to improve microvas-
cular blood flow in PAD. This review aims to summarize different 
approaches that have been used to identify miRNAs involved in 
PAD and the potential for miRNAs as a therapy for PAD.
MicroRNA expression in proangiogenic cells of  
CLI patients
The vascular system develops during the process of  embryogen-
esis. This vasculogenesis was initially thought to occur only dur-
ing embryonic development, howeverit is now known that this 
process occurs to some degree in the postnatal life [22].Situated 
within the bone marrow are non-hematopoietic progenitors, in-
cluding endothelial progenitor cells (EPCs)/ Proangiogenic Cells 
(PACs) [23]. These EPCs are capable of  being recruited to sites 
of  arterial injury to participate in neovascularization [24].Specific 
markers expressed by these cells include VEGR2, VE-cadherin, 
CD31 and CD133 [25]. Spinetti et al. screened the PACs of  CLI 
patients with and without diabetes and controls for 28 miRs that 
potentially modulated angiogenesis and found eighteen differen-
tially regulated miRs. Two miRs, miR-15a and 16 were chosen for 
further analysis based on their potential role in angiogenesis and 
ischemia. PCR analysis revealed an elevation of  miR-15a and 16 in 
the PACs as well as in the serum of  CLI patients with or without 
diabetes. When hypoxia was used to stimulate ischemia in vitro, 
increased miR15a and 16 expressionwas noted in healthy PACs. 
Overexpression of  both miRs in PACs increased apoptosis, while 
inhibition corrected it. Additionally, in vivo studies confirmed that 
ischemic mouse adductor muscles treated with anti-miR-15a/16 
PACs had increased blood flow recovery and arteriole density, 
while those receiving pre-miR-15a/16 PACs displayed impaired 
perfusion recovery and a reduced number of  capillaries com-
pared to negative controls [26].This model provides preliminary 
data that PACs enriched with miR15a/16 may serve as a potential 
therapeutic target in PAD.
MiRNAs in ischemic vs. non-ischemic muscle
A cluster of  microRNAs, miR-17~92, has been shown to be up-
regulated in tumors and promotes tumor angiogenesis [27,28]. 
Bonaeur et al. showed that this microRNA cluster, particularly 
mir-92a, is expressed in human endothelial cells. Using a mouse 
hind-limb ischemic model, they showed an upregulation in the 
expression of  miR-92a in the ischemic limb compared to the non-
ischemic limb, with maximal effects seen within the first three 
days following injury. Furthermore, mice injected with an inhibi-
tor, antagomir-92a, had a significant reduction in toe necrosis and 
improved perfusion compared to those injected with a negative 
control [29].
Similar results were observed in a different ischemic condition, 
whereacute myocardial infarction was also found to upregulate 
miR92a.Bonaeur et al. injected antagomir-92a or a control at vari-
ous days following left coronary artery occlusion. Mice treated 
with anatgomir-92a exhibited improved left and right ventricular 
function compared to controls. Additionally, infarct size and num-
ber of  apoptotic cells were also reduced. Despite being proangio-
genic in tumor cells, miR92a was found to be antiangiogenic in 
ischemic endothelial cells.
Grundman et al. performed a microarray analysis on RNA iso-
lated from adductor muscle of  C57BL/6J mice at baseline and 
multiple time points following femoral arterial ligation. 
They identified numerous miRNAs that were upregulated and 
downregulated, however, miR-100 was the most consistently 
downregulatedmiR at day three after femoral artery ligation. To 
confirm that these changes in expression were related to vascular 
structures collateral arteries from hind limb at day 3 after femoral 
artery ligation were isolated. Both the growing collateral arteries 
of  the ischemic limb and the non-proliferating arterial anasto-
mosis of  the non-ischemic limb expressed miR-100. However,the 
expression of  miR-100 was significantly decreased in the grow-
ing collateral arteries of  the ischemic limb compared to nonpro-
liferating, quiescent vessels from ischemic limb. No differences 
were noted between the growing and quiescent vessel of  the 
non-ischemic limb. Moreover, endothelial cells were isolated and 
revealed a decrease miR-100 expression in ischemic endothelial 
cells compared to non-ischemic endothelial cells at day 3 follow-
ing ligation [30].
To investigate targets of  miR-100, endothelial cells over expressing 
miR-100 were analyzed by micro array which revealed hundreds 
of  potential mRNA targets. These potential targets were entered 
in two bioinformatics algorithms and 8 targets were common to 
both, including the mammalian target of  rapamycin (mTOR), a 
proangiogenic gene. Furthermore, inhibition of  miR-100 with an 
anatagomir injection given to C57BL/6J mice before and for two 
days following hind-limb ischemia resulted in enhanced perfusion 
recovery measured by Doppler imaging [30].Mice receiving an 
mTOR inhibitor, rapamycin, resulted in reduction of  blood flow 
recovery following 7 days after femoral artery ligation.
Differentially regulated microRNAs in two phe-
notypically distinct mouse strains
It has been established that two mouse strains, BALB/cJ and 
C57Bl/6J, recover differently following hind-limb ischemia 
(HLI). Whereas the C57Bl/6J strain recovers well following HLI, 
BALB/cJ miceexhibit poor perfusion recovery [31,32].With this 
knowledge, Hazarikaet al. performed a miroRNAmicro-array 
analysis of  ischemic gastrocnemius muscles of  these two strains 
and found that C57BL/6J had a greater upregulationof  miR-93 
following ischemia.The expression of  miR-93 was increased in 
ischemic muscle of  C57Bl/6J at a time point when perfusion 
recovery in both strains were similar (day 3), and remained el-
evated at day 7 post-surgery. Moreover, the C57BL/6 strain also 
expressed higher levels of  miR-93 in the non-ischemic muscle 
compared to BALB/c [33].
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In vivo studies involving gain of  function and loss of  func-
tion further solidified the role of  miR-93 in perfusion recovery. 
C57Bl/6J mice treated with antagomir-93 at day 0, 7 and 14 post 
HLI had impaired perfusion starting at day 14 compared to the 
negative control. Moreover, a gain of  function technique in which 
BALBC/cJ mice received a local intramuscular injection of  pre-
miR 93, resulting in overexpression of  the miR93, showed en-
hanced perfusion recovery as well as higher capillary density com-
pared to the negative control. The effects of  this microRNA are 
thought to be the result of  multiple genes [33]. Taken together, 
this unbiased model using distinct phenotypic outcomes between 
two inbred mouse strains following HLI confirmed miR-93 as 
the most consistent differentially regulated micro-RNA based on 
strain and ischemia and solidifies its role in perfusion recovery.
MicroRNAs in a diabetic ischemic model
As stated before, diabetes is a major risk factor for PAD. The hy-
perglycemic state leads to endothelial cell dysfunction and vessel 
wall remodeling and thus an increase in ischemic complications 
[34]. Diabetics have poor recovery following ischemic insults due 
to impaired reparative angiogenesis [34]. Caporali et al. found an 
upregulation of  miR-503 in cultured conditions mimicking dia-
betes mellitus (DM) and ischemia. This prompted further in vivo 
studies of  this miR. They used a type 1 diabetic mice model us-
ing CD1 male mice and found that expression of  miR-503 was 
significantly higher in the ischemic adductor muscles of  diabetic 
mice compared to non-diabetic and/or non-ischemic controls at 
day 3 post ischemia [35].
Moreover, efficient inhibition of  miR-503 using a decoy for 
miR-503, Ad.decoymir-503, improved blood flow recovery in 
diabetic mice as well as increased capillary and arteriolar density 
in ischemic muscle. The target genes, cdc25A and CCNE1, were 
down regulated by diabetes mellitus but returned to normal levels 
by inhibition of  miR-503 at day 3 and 21 post ischemia. To fur-
ther strengthen the role of  miR-503 in diabetes and ischemia, it 
was found that diabetic patients undergoing amputation for CLI 
had an increase expression of  miR-503 in calf  muscle compared 
to non-diabetics and non-ischemic control patients undergoing 
saphenous vein stripping (n=11 each group, p<0.05) [35].
MicroRNAs in Arteriosclerosis Obliterans
Li et al. designed a study which enrolled 104 patients with ar-
teriosclerosis obliterans (ASO) and 105 age-matched controls in 
order to determine which miRNAs were differentially expressed 
between these two groups. Based on their known association with 
vascular biology, a selected set of  miRNAs, (miR-21, miR-221, 
miR-222, miR-145, miR-143, miR-27b, miR-130a, let-7f, miR-378, 
miR-210, miR-15, miR-16 and miR-126) were examined in intima 
samples. Levels of  miR-21, miR-130a, miR-27b, let-7f  and miR-
210 showed significant increase, while miR-221, miR-222 were 
downregulatedin diseased samples compared to controls [36].
After establishing the expression levels in the intima, these miRs 
were then examined in the serum of  the 104 ASO patients and 105 
controls. Results revealed an increase in miR-21, miR-130a, miR-
27b and miR-210 with no difference in the expression of  miR-
221, miR-222 or let-7f. Furthermore, serum levels of  miR130a, 
miR27b and miR-210 were increased at each fontaine stage, with 
the expression of  miR-27b significantly increasing with each ad-
vancement offontaine stage [36].Taken together these results sug-
gest that these miRNAs may be used as potential risk markers for 
diagnosing ASO at earlier stages or serve as a severity indicator. 
With further studies and better understanding of  the microRNAs 
it may be possible to manipulate their effects fto establish a thera-
peutic agent. 
Discussion 
Peripheral arterial disease affects millions of  individuals world-
wide, yet treatment strategies remain subpar. Late diagnosis cou-
pled with ineffective treatment has led to a large burden on the 
healthcare system as well as increasing mortality rate.Understand-
ing the mechanisms involved in the pathophysiology of  PAD is 
crucial in identifying new therapeutic agents. The ability to form 
new blood vessels is an important mechanism following occlu-
sion of  an artery and multiple studies have shown that many mi-
croRNAs play a role in inhibiting and stimulating this angiogenic 
process. Though surgical intervention has been used in patients 
with CLI, many patients may not be candidates for such surgi-
cal treatment and those experiencing initial success may then face 
complications such as graft failure or stenosis.  Additionally, there 
is evidence that repairing occlusions of  large vessels may not im-
prove perfusion or ABI, suggesting at least in some individuals, 
the disease is primarily in the microvasculature.
MiRNA’s have been successfully manipulated to improve out-
Table 1.Summary ofmicroRNAs along with their targets, how they were identified and their effect on perfusion
Micro RNA Targets How it was identified Effect
miR-15a/16 VEGF-A, AKT-3 PCR analysis of  PACs from healthy 
patients and CLI patients with and 
without T2DM
Impairs perfusion
miR-92a Integrin subunits α5 
(ITGA5) and αv, S1P1, and 
MKK4
PCR analysis of  human endothelial 
cells
Impairs perfusion
miR-100 Target gene mammalian tar-
get of  rapamycin (mTOR)
Microarray analysis of  C57BL/6J 
mice adductor muscles
Impairs perfusion 
miR-93 P21, E2F-1, P53 PCR analysis of  ischemic muscle of  
two phenotypically different mouse 
strains 
Improves perfusion 
miR-503 CCNE1 and cdc25A PCR analysis of  culture endothelial 
cells in conditions mimicking diabetes 
and ischemia
Impairs perfusion
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comes in the above preclinical models of  PAD.Table 1 suggests a 
strategy that involves overexpression of  miR-93 or inhibition of  
miR-15a, miR-16, miR-92a, miR-100 and miR-503 may be effec-
tive.  However, many factors must be taken into account in the 
development of  these therapeutic approaches in order  to achieve 
success.For example, the current studies have been inpre-clinical 
models of  PAD in mice, where systemic injection or local injec-
tion of  microRNA mimics or antagomirs have been used success-
fully. However, the sort of  dosing regimen used in mice may not 
be translatable to humans. It would be important to determine 
whether systemic vs local administration would be the most effec-
tive in achieving expression of  pre-miRNA or antagomirs in the 
lower extremities of  humans with PAD. Another concern is the 
possibility of  off  target effects of  these miRNAs which has the 
potential to increase side effects.Research involving microRNAs 
is evolving due to its emerging roles in disease pathophysiology. 
With the first therapeutic microRNA currently in phase I clinical 
trials for the treatment of  liver cancer, manipulation of  mRNAs 
holds promise for a potential target for improving patient out-
comes in PAD.
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